Discover Expert Perspectives

In this article, Jason (Legal Lead, ClavystBio) will walk through, in plain terms, how staged (or "tranched") financing works, why investors in our field so often ask for it, and the handful of things worth sorting out before you sign.

ClavystBio brings together founders, partners, and capital to translate breakthrough science into patient impact through a committed global ecosystem. Perspectives from portfolio companies and strategic partners highlight portfolio momentum in 2025 and ClavystBio’s role in strengthening connections across Singapore, the US, Europe, Japan, and Asia.

How is clinical development evolving—and what does it mean for biotech innovation? Dr. Amy Abernethy (Highlander Health) shared insights on the future of trials, from AI and real-world data to accelerated approvals and global regulatory shifts.

Thinking of setting up your own BSL-2 lab in Singapore? Full control is great — but the reality can be a heavy lift. This article unpacks the key costs and considerations, and offers alternatives if you’re not ready to go all-in.

Co-organized with Enterprise Singapore, Droia’s Managing Partner Luc Dochez and leading pharma and biotech executive Andreas Wallnoefer provide invaluable insights into navigating successful biotech deal negotiations and partnerships.

What does it take to truly connect with a big pharma? We unpacked this during a valuable discussion with MSD’s Discovery Leads Marc Levesque (Immunology), David Weinstock (Oncology), Erin Whalen (Cardiometabolic Research) and Director of BD and Licensing Koji Yashiro.